{
    "info": {
        "nct_id": "NCT03682068",
        "official_title": "A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination With Standard of Care Chemotherapy and Durvalumab in Combination With Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients With Unresectable Locally Advanced or Metastatic Urothelial Cancer.",
        "inclusion_criteria": "* Patients with histologically or cytologically documented, unresectable, locally advanced or metastatic transitional cell carcinoma (transitional cell and mixed transitional/non-transitional cell histologies) of the urothelium (including renal pelvis, ureters, urinary bladder, and urethra)\n* Patients who have not been previously treated with first-line chemotherapy. Patients who have received prior definitive chemoradiation, adjuvant or neoadjuvant treatment for locally advanced disease are eligible provided that progression to locally advanced or metastatic disease has occurred >12 months from the last therapy [for chemoradiation and adjuvant treatment] or >12 months from the last surgery [for neoadjuvant treatment].\n* At least 1 lesion, not previously irradiated, that qualifies as a RECIST 1.1 target lesion at baseline.\n* World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 at enrolment\n* Adequate organ and marrow function as defined in the protocol\n* Life expectancy ≥12 weeks in the opinion of the investigator\n* Evidence of post-menopausal status, or negative urinary or serum pregnancy test for female pre-menopausal patients.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 130 Years",
        "exclusion_criteria": "* Prior exposure to immune-mediated therapy (with exclusion of Bacillus Calmette Guerin), including but not limited to, other anti-CTLA-4, anti-PD-1, anti-PD L1, or anti-PD-L2 antibodies, except therapeutic anticancer vaccines, which are permitted. Prior local intervesical chemotherapy or immunotherapy is allowed if completed at least 28 days prior to the initiation of study treatment.\n* No severe concomitant condition that requires immunosuppression medication\n* Untreated central nervous system (CNS) metastases and/or carcinomatous meningitis\n* Patients who may be eligible for or are being considered for radical resection during the course of the study.\n* Any medical contraindications to platinum (cisplatin or carboplatin) based doublet chemotherapy and/or known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients",
        "miscellaneous_criteria": "Key"
    },
    "inclusion_lines": [
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "volunteer health status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "healthy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Key",
            "criterions": [
                {
                    "exact_snippets": "Key",
                    "criterion": "key",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": "N/A"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Evidence of post-menopausal status, or negative urinary or serum pregnancy test for female pre-menopausal patients.",
            "criterions": [
                {
                    "exact_snippets": "Evidence of post-menopausal status",
                    "criterion": "post-menopausal status",
                    "requirements": [
                        {
                            "requirement_type": "evidence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "negative urinary or serum pregnancy test for female pre-menopausal patients",
                    "criterion": "pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have maximum age of 130 Years",
            "criterions": [
                {
                    "exact_snippets": "maximum age of 130 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 130,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy ≥12 weeks in the opinion of the investigator",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy ≥12 weeks",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "in the opinion of the investigator",
                    "criterion": "investigator's opinion",
                    "requirements": [
                        {
                            "requirement_type": "consideration",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate organ and marrow function as defined in the protocol",
            "criterions": [
                {
                    "exact_snippets": "Adequate organ and marrow function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate organ and marrow function",
                    "criterion": "marrow function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 at enrolment",
            "criterions": [
                {
                    "exact_snippets": "World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 at enrolment",
                    "criterion": "performance status",
                    "requirements": [
                        {
                            "requirement_type": "scale",
                            "expected_value": [
                                "0",
                                "1"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* At least 1 lesion, not previously irradiated, that qualifies as a RECIST 1.1 target lesion at baseline.",
            "criterions": [
                {
                    "exact_snippets": "At least 1 lesion",
                    "criterion": "lesion count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "not previously irradiated",
                    "criterion": "lesion irradiation status",
                    "requirements": [
                        {
                            "requirement_type": "irradiation",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "qualifies as a RECIST 1.1 target lesion",
                    "criterion": "RECIST 1.1 target lesion qualification",
                    "requirements": [
                        {
                            "requirement_type": "qualification",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "at baseline",
                    "criterion": "baseline status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "baseline"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have not been previously treated with first-line chemotherapy. Patients who have received prior definitive chemoradiation, adjuvant or neoadjuvant treatment for locally advanced disease are eligible provided that progression to locally advanced or metastatic disease has occurred >12 months from the last therapy [for chemoradiation and adjuvant treatment] or >12 months from the last surgery [for neoadjuvant treatment].",
            "criterions": [
                {
                    "exact_snippets": "Patients who have not been previously treated with first-line chemotherapy.",
                    "criterion": "previous first-line chemotherapy treatment",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients who have received prior definitive chemoradiation, adjuvant or neoadjuvant treatment for locally advanced disease are eligible provided that progression to locally advanced or metastatic disease has occurred >12 months from the last therapy [for chemoradiation and adjuvant treatment]",
                    "criterion": "progression after chemoradiation or adjuvant treatment",
                    "requirements": [
                        {
                            "requirement_type": "time since last therapy",
                            "expected_value": {
                                "operator": ">",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "progression to locally advanced or metastatic disease has occurred ... >12 months from the last surgery [for neoadjuvant treatment].",
                    "criterion": "progression after neoadjuvant treatment",
                    "requirements": [
                        {
                            "requirement_type": "time since last surgery",
                            "expected_value": {
                                "operator": ">",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with histologically or cytologically documented, unresectable, locally advanced or metastatic transitional cell carcinoma (transitional cell and mixed transitional/non-transitional cell histologies) of the urothelium (including renal pelvis, ureters, urinary bladder, and urethra)",
            "criterions": [
                {
                    "exact_snippets": "histologically or cytologically documented",
                    "criterion": "transitional cell carcinoma documentation",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "unresectable",
                    "criterion": "resectability of carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "resectability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "locally advanced or metastatic",
                    "criterion": "stage of carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "locally advanced",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "transitional cell carcinoma (transitional cell and mixed transitional/non-transitional cell histologies)",
                    "criterion": "carcinoma histology",
                    "requirements": [
                        {
                            "requirement_type": "histology",
                            "expected_value": [
                                "transitional cell",
                                "mixed transitional/non-transitional cell"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "urothelium (including renal pelvis, ureters, urinary bladder, and urethra)",
                    "criterion": "carcinoma location",
                    "requirements": [
                        {
                            "requirement_type": "location",
                            "expected_value": [
                                "urothelium",
                                "renal pelvis",
                                "ureters",
                                "urinary bladder",
                                "urethra"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Patients who may be eligible for or are being considered for radical resection during the course of the study.",
            "criterions": [
                {
                    "exact_snippets": "Patients who may be eligible for or are being considered for radical resection",
                    "criterion": "eligibility for radical resection",
                    "requirements": [
                        {
                            "requirement_type": "consideration",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any medical contraindications to platinum (cisplatin or carboplatin) based doublet chemotherapy and/or known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients",
            "criterions": [
                {
                    "exact_snippets": "Any medical contraindications to platinum (cisplatin or carboplatin) based doublet chemotherapy",
                    "criterion": "medical contraindications to platinum-based doublet chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "known allergy or hypersensitivity to any of the study drugs",
                    "criterion": "allergy or hypersensitivity to study drugs",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "known allergy or hypersensitivity to ... any of the study drug excipients",
                    "criterion": "allergy or hypersensitivity to study drug excipients",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No severe concomitant condition that requires immunosuppression medication",
            "criterions": [
                {
                    "exact_snippets": "No severe concomitant condition",
                    "criterion": "concomitant condition",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "not severe"
                        }
                    ]
                },
                {
                    "exact_snippets": "requires immunosuppression medication",
                    "criterion": "immunosuppression medication",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Untreated central nervous system (CNS) metastases and/or carcinomatous meningitis",
            "criterions": [
                {
                    "exact_snippets": "Untreated central nervous system (CNS) metastases",
                    "criterion": "central nervous system (CNS) metastases",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        }
                    ]
                },
                {
                    "exact_snippets": "carcinomatous meningitis",
                    "criterion": "carcinomatous meningitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior exposure to immune-mediated therapy (with exclusion of Bacillus Calmette Guerin), including but not limited to, other anti-CTLA-4, anti-PD-1, anti-PD L1, or anti-PD-L2 antibodies, except therapeutic anticancer vaccines, which are permitted. Prior local intervesical chemotherapy or immunotherapy is allowed if completed at least 28 days prior to the initiation of study treatment.",
            "criterions": [
                {
                    "exact_snippets": "Prior exposure to immune-mediated therapy (with exclusion of Bacillus Calmette Guerin)",
                    "criterion": "prior exposure to immune-mediated therapy",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": [
                                "Bacillus Calmette Guerin"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior exposure to ... other anti-CTLA-4, anti-PD-1, anti-PD L1, or anti-PD-L2 antibodies",
                    "criterion": "prior exposure to specific antibodies",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": [
                                "anti-CTLA-4",
                                "anti-PD-1",
                                "anti-PD L1",
                                "anti-PD-L2"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "therapeutic anticancer vaccines, which are permitted",
                    "criterion": "prior exposure to therapeutic anticancer vaccines",
                    "requirements": [
                        {
                            "requirement_type": "permitted",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior local intervesical chemotherapy or immunotherapy is allowed if completed at least 28 days prior to the initiation of study treatment",
                    "criterion": "prior local intervesical chemotherapy or immunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "completion time",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [
        {
            "line": "Key",
            "criterions": [
                {
                    "exact_snippets": "Key",
                    "criterion": "key",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": "N/A"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}